Thus, the difference in cathepsin B activity we observed in the cases of AD-DS compared with EOAD is likely to be caused by a specific effect of three copies of Hsa21 on enzyme function and not the result of differences in tau pathology in the cases. This evidence concerns the gene MAPT and Alzheimer disease.